Immunomodulatory Therapy for Rasmussen Syndrome

Investigators from the National Epilepsy Center, Shizuoka, Gifu University, Tokyo Women’s Medical University, National Center of Neurology and Psychiatry, and Okayama University School of Medicine, Japan, examined seizure, cognitive, and motor outcomes in 49 patients referred with Rasmussen encephalitis (RS) and recently had received initial immunomodulatory therapy: regular IV immunoglobulin (IVIg) at a dose of 100 mg/kg/day, methylprednisolone steroid pulse therapy at a dose of 30 mg/kg/day (children) for 3 days, and tacrolimus 0.1 mg/kg/day.